Section II: Object
II.1)Scope of the procurement
II.1.1)Title:
2022-3-15 SEGUNDA MODIF. SUMINISTRO DE VARIOS MEDICAMENTOS DE DISTRIBUCIÓN EXCLUSIVA DE LA FIRMA NOVARTIS FARMACEUTICA, S.A. PARA EL H. UNIVERSITARIO 12 DE OCTUBRE.
Reference number: 2022-3-15
II.1.2)Main CPV code
33600000 Pharmaceutical products
II.1.3)Type of contract
Supplies
II.2)Description
II.2.1)Title:
XOLAIR 150 MG SOLUC. INYECTABLE, 1 JERINGA PRECARGADA DE 1 ML
Lot No: 1
II.2.2)Additional CPV code(s)
33600000 Pharmaceutical products
II.2.3)Place of performance
NUTS code: ES300 Madrid
II.2.4)Description of the procurement at the time of conclusion of the
contract:
2022- 3-15 SUMINISTRO DE VARIOS MEDICAMENTOS DE DISTRIBUCIÓN EXCLUSIVA DE LA FIRMA "NOVARTIS FARMACÉUTICA, S.A.” PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDADES RESPIRATORIAS,
ONCOLÓGICAS, NEUROLÓGICAS O TRASPLANTADOS, CON DESTINO AL SERVICIO DE FARMACIA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
II.2.7)Duration of the contract, framework agreement, dynamic purchasing system or
concession
Duration in months: 12
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
Section V: Award of contract/concession
Title:
SUMINISTRO DE VARIOS MEDICAMENTOS EXCLUSIVOS DE LA FIRMA NOVARTIS FARMACEUTICA, S.A. PARA EL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
V.2)Award of contract/concession
V.2.1)Date of conclusion of the contract/concession award decision:
13/07/2022
V.2.2)Information about tenders
The contract/concession has been awarded to a group of economic operators: no
V.2.3)Name and address of the contractor/concessionaire
Official name: NOVARTIS FARMACÉUTICA, S.A
Town: Barcelona
NUTS code: ES511 Barcelona
Country: Spain
The contractor/concessionaire is an SME: no
V.2.4)Information on value of the contract/lot/concession (at the time of conclusion
of the contract;excluding VAT)
Total value of the procurement: 2 350 329.19 EUR
Section VI: Complementary information
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: SERVICIO MADRILEÑO DE SALUD - HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
Postal address: AVENIDA DE CÓRDOBA, SIN NÚMERO
Town: MADRID
Postal code: 28041
Country: Spain
Telephone: +34 913908913/8552
Fax: +34 913908181
VI.4.2)Body responsible for mediation procedures
Official name: NO PROCEDE
Town: Madrid
Country: Spain
VI.4.4)Service from which information about the review procedure may be
obtained
Official name: HOSPITAL UNIVERSITARIO 12 DE OCTUBRE.
Postal address: AVENIDA DE CÓRDOBA, SIN NÚMERO
Town: MADRID
Postal code: 28041
Country: Spain
Telephone: +34 913908913/8552
VI.5)Date of dispatch of this notice:
14/09/2023
Section VII: Modifications to the contract/concession
VII.1)Description of the procurement after the modifications
VII.1.1)Main CPV code
33600000 Pharmaceutical products
VII.1.2)Additional CPV code(s)
VII.1.3)Place of performance
NUTS code: ES300 Madrid
VII.1.4)Description of the procurement:
SUMINISTRO DE VARIOS MEDICAMENTOS DE DISTRIBUCIÓN EXCLUSIVA DE LA FIRMA NOVARTIS FARMACÉUTICA, S.A. PARA EL SERVICIO DE FARMACIA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
VII.1.5)Duration of the contract, framework agreement, dynamic purchasing system or
concession
Start: 01/02/2023
End: 13/07/2023
VII.1.6)Information on value of the contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: 2 345 302.17 EUR
VII.1.7)Name and address of the contractor/concessionaire
Official name: NOVARTIS FARMACÉUTICA S.A.
Town: Barcelona
NUTS code: ES511 Barcelona
Country: Spain
The contractor/concessionaire is an SME: no
VII.2)Information about modifications
VII.2.1)Description of the modifications
Nature and extent of the modifications (with indication of possible earlier changes to the contract):
Segunda modificación en menor importe del contrato, debido al cambio de precio en el lote 5 (Mekinist 2 mg 30 comprimidos), con efectividad a partir el 01 de febrero de 2023.
VII.2.2)Reasons for modification
Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee (Art. 43(1)(c) of Directive 2014/23/EU, Art. 72(1)(c) of Directive
2014/24/EU, Art. 89(1)(c) of Directive 2014/25/EU)
Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:
Segunda modificación en menor importe del contrato, debido al cambio de precio en el lote 5 (Mekinist 2 mg 30 comprimidos), con efectividad a partir el 01 de febrero de 2023.
VII.2.3)Increase in price
Updated total contract value before the modifications (taking into account possible earlier contract modifications and price adaptions and, in the case of Directive 2014/23/EU,
average inflation in the Member State concerned)
Value excluding VAT: 2 346 641.90 EUR
Total contract value after the modifications
Value excluding VAT: 2 345 302.17 EUR